Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK4 | Q9HAZ1 | 9/20 | 0.66 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.66 |
| ▸ | PDE5A | O76074 | 1/20 | 0.54 |
| ▸ | VNN1 | O95497 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | CLK1 | P49759 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34462781 | 0.85 | CLK4 (0.56) | CLK4DYRK1AVNN1ALDH1A1CYP1A2 | |
| SCHEMBL3399312 | 0.85 | CLK4 (0.57) | CLK4DYRK1APDE5AVNN1ALDH1A1 | |
| SCHEMBL3397266 | 0.84 | CLK4 (0.56) | CLK4DYRK1APDE5AVNN1CLK1 | |
| SCHEMBL3363498 | 0.82 | CLK4 (0.54) | CLK4DYRK1APDE5AVNN1ALDH1A1 | |
| SCHEMBL16177732 | 0.82 | CYP1A2 (0.69) | CLK4ALDH1A1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL16185278 | 0.82 | CYP1A2 (0.54) | CLK4DYRK1AALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL8422251 | 0.81 | MEN1 (0.68) | CLK4DYRK1AALDH1A1KDM4ECLK1 | |
| SCHEMBL28131061 | 0.80 | CLK4 (0.57) | CLK4DYRK1AKDM4ECLK1NPC1 | |
| SCHEMBL22122521 | 0.80 | PDE5A (0.56) | CLK4DYRK1APDE5AVNN1ALDH1A1 | |
| SCHEMBL953773 | 0.80 | TSHR (0.56) | CLK4DYRK1APDE5AVNN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3372601-B1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2022-09-21 | — | — | EP | disclosed |
| US-10793582-B2 | Bicyclic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2020-10-06 | — | — | US | disclosed |
| US-10793582-B2 | Bicyclic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2020-10-06 | — | — | US | disclosed |
| US-10717738-B2 | Pyrimidinone and its derivatives inhibiting factor XIa | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-07-21 | — | — | US | disclosed |
| EP-3290413-B9 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO PHARMACEUTICAL CO (JP) | 2020-04-29 | — | — | EP | disclosed |
| EP-3290413-B1 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO PHARMACEUTICAL CO (JP) | 2019-11-13 | — | — | EP | disclosed |
| US-20190233438-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-08-01 | — | — | US | disclosed |
| US-20190233438-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-08-01 | — | — | US | disclosed |
| EP-3372601-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2018-09-12 | — | — | EP | disclosed |
| EP-2794597-B1 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO PHARMACEUTICAL CO (JP) | 2017-11-15 | — | — | EP | disclosed |
| US-20050153960-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2005-07-14 | — | — | US | disclosed |
| EP-1537084-A1 | SUBSTITUTED 2-ALKYLAMINE NICOTINIC AMIDE DERIVATIVES AND USE THERE OF | Amgen Inc. (US) | 2005-06-08 | — | — | EP | disclosed |
| US-6878714-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2005-04-12 | — | — | US | disclosed |
| US-20040204437-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2004-10-14 | — | — | US | disclosed |
| WO-2004007458-A1 | SUBSTITUTED 2-ALKYLAMINE NICOTINIC AMIDE DERIVATIVES AND USE THERE OF | AMGEN INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004007457-A2 | SUBSTITUTED BENZYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004007481-A2 | SUBSTITUTED AMINE DERIVATIVES AND METHODS OF USE IN THE TREATMENT OF ANGIOGENESIS RELATES DISORDERS | AMGEN INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-12-04 | — | — | US | disclosed |
| US-20030203922-A1 | Substituted amine derivatives and methods of use | AMGEN INC. | 2003-10-30 | — | — | US | disclosed |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2003-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153960-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | CLK4 4298/4885DYRK1A 2470/4885PDE5A 318/4885 |
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | NAT1, PIGO, AADAC | CLK4 4114/4885DYRK1A 3566/4885PDE5A 128/4885 |
| US-20040204437-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | CLK4 4298/4885DYRK1A 2470/4885PDE5A 318/4885 |
| US-20190233438-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | KAT2A, KAT7, KAT5 | CLK4 1016/4885DYRK1A 4256/4885PDE5A 2534/4885 |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | CLK4 4298/4885DYRK1A 2470/4885PDE5A 318/4885 |
| US-20030203922-A1 | Substituted amine derivatives and methods of use | MAOB, HNMT, FLT4 | CLK4 3435/4885DYRK1A 2254/4885PDE5A 75/4885 |
| US-10717738-B2 | Pyrimidinone and its derivatives inhibiting factor XIa | F11, TFPI, F10 | CLK4 4767/4885DYRK1A 3716/4885PDE5A 634/4885 |
| US-10793582-B2 | Bicyclic heterocyclic compound | KAT2A, KAT7, KAT5 | CLK4 1116/4885DYRK1A 4411/4885PDE5A 3131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.